Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Alliance Pharma stock price, quote, forecast and news

APH.L
GB0031030819
913253

Price

0.37 GBP
Today +/-
+0.00 GBP
Today %
+0.81 %
P

Alliance Pharma stock price

GBP
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Alliance Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Alliance Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Alliance Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Alliance Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Alliance Pharma Stock Price History

DateAlliance Pharma Price
8/23/20240.37 GBP
8/22/20240.37 GBP
8/21/20240.37 GBP
8/20/20240.36 GBP
8/19/20240.37 GBP
8/16/20240.37 GBP
8/15/20240.37 GBP
8/14/20240.37 GBP
8/13/20240.36 GBP
8/12/20240.37 GBP
8/9/20240.36 GBP
8/8/20240.36 GBP
8/7/20240.35 GBP
8/6/20240.35 GBP
8/5/20240.35 GBP
8/2/20240.37 GBP
8/1/20240.38 GBP
7/31/20240.38 GBP
7/30/20240.37 GBP
7/29/20240.38 GBP

Alliance Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Alliance Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Alliance Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Alliance Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Alliance Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Alliance Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Alliance Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Alliance Pharma’s growth potential.

Alliance Pharma Revenue, EBIT and net profit per share

DateAlliance Pharma RevenueAlliance Pharma EBITAlliance Pharma Net Income
2029e258.69 M GBP0 GBP0 GBP
2028e252.41 M GBP62.21 M GBP0 GBP
2027e236.95 M GBP53.23 M GBP34.8 M GBP
2026e214.85 M GBP44.69 M GBP31.57 M GBP
2025e208.34 M GBP42.64 M GBP28.18 M GBP
2024e195.03 M GBP40.83 M GBP24.66 M GBP
2023180.68 M GBP34.66 M GBP-33.14 M GBP
2022167.42 M GBP28.43 M GBP-21.21 M GBP
2021163.21 M GBP30.57 M GBP7.32 M GBP
2020129.8 M GBP29.67 M GBP8.03 M GBP
2019135.64 M GBP37.45 M GBP25.01 M GBP
2018118.21 M GBP28.92 M GBP18.36 M GBP
2017101.64 M GBP25.8 M GBP28.83 M GBP
201697.49 M GBP25.31 M GBP18.09 M GBP
201548.34 M GBP12.28 M GBP12.69 M GBP
201443.54 M GBP11.47 M GBP8.39 M GBP
201345.5 M GBP13.4 M GBP9.6 M GBP
201244.9 M GBP12.3 M GBP8.7 M GBP
201146 M GBP12.3 M GBP8.6 M GBP
201049.9 M GBP18.7 M GBP9 M GBP
200931.2 M GBP11.2 M GBP4.1 M GBP
200821.8 M GBP6.4 M GBP2.5 M GBP
200718.2 M GBP3.6 M GBP-3 M GBP
200617.3 M GBP2.6 M GBP500,000 GBP
200512.3 M GBP2 M GBP700,000 GBP
200411.8 M GBP2.3 M GBP400,000 GBP

Alliance Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M GBP)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M GBP)EBIT (M GBP)EBIT MARGIN (%)NET INCOME (M GBP)NET INCOME GROWTH (%)DIV. (GBP)DIV. GROWTH (%)SHARES (B)DOCUMENTS
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0366681011121718213149464445434897101118135129163167180195208214236252258
--100.00--33.3325.0010.009.0941.675.8816.6747.6258.06-6.12-4.352.27-4.4411.63102.084.1216.8314.41-4.4426.362.457.788.336.672.8810.286.782.38
--16.6716.6716.6725.0050.0054.5550.0052.9444.4452.3858.0661.2252.1756.8260.0058.1458.3355.6758.4261.0263.7063.5766.8760.4858.33------
0011125669811183024252725285459728682109101105000000
00000012223611181212131112252528372930283440424453620
------10.0018.1816.6711.7616.6728.5735.4836.7326.0927.2728.8925.5825.0025.7724.7523.7327.4122.4818.4016.7718.8920.5120.1920.5622.4624.60-
000000-2000-32498898121828182587-21-332428313400
------------166.67100.00125.00-11.11-12.50-11.1150.0050.0055.56-35.7138.89-68.00-12.50-400.0057.14-172.7316.6710.719.68--
---------------------------------
---------------------------------
0.070.070.070.070.070.070.080.120.150.16162.060.20.210.250.260.260.270.270.280.470.480.510.530.540.540.540.54000000
---------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Alliance Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Alliance Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M GBP)RECEIVABLES (M GBP)OTHER REC. (M GBP)INVENTORIES (M GBP)OTHER CURRENT LIAB. (M GBP)CURRENT ASSETS (M GBP)TANGIBLE ASSETS (M GBP)LONG-T. INVEST. (M GBP)LONG-T. REC. (M GBP)INTANGIBLE ASSETS (M GBP)GOODWILL (M GBP)OTHER NON-CURRENT ASSETS (M GBP)NON-CURRENT ASSETS (M GBP)TOTAL ASSETS (M GBP)LIABILITIESCOMMON STOCK (M GBP)ADDITIONAL PAID-IN CAPITAL (M GBP)RETAINED EARNINGS (M GBP)OTHER EQUITY (M GBP)UNREAL. GAINS/LOSSES (M GBP)EQUITY (M GBP)LIABILITIES (M GBP)PROVISIONS (M GBP)OTHER SHORT-TERM LIAB. (M GBP)SHORT-TERM DEBTS (M GBP)LONG-TERM DEBT PORTION (M GBP)SHORT-TERM REC. (M GBP)LONG-T. LIAB. (M GBP)DEFERRED TAXES (M GBP)OTHER LIAB. (M GBP)LONG-T. LIABILITIES (M GBP)DEBT (M GBP)TOTAL CAPITAL (M GBP)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
020000.24.61.4000.701.121.14.60.91.43.237.2211.1810.8917.8328.929.0631.7122.44
0.10.60.90.70.71.51.71.82.64.74.15.97.39.28.29.69.27.210.0422.8119.4723.4127.7722.6725.7745.4649.97
00.60.100.1000.10.10.10.10.30.10.10.10.20.50.71.061.791.761.082.521.541.952.781.72
01.11.41.41.71.91.72.52.72.91.92.334.55.75.45.55.912.9115.3614.2518.7115.5222.9221.0824.2925.71
00.100.10.10.10.20.20.30.40.20.20.30.40.30.40.80.50.532.112.474.661.41.213.171.254.26
0.14.42.42.22.63.78.265.78.178.711.816.215.420.216.915.727.7749.2849.1358.7565.0477.2481.02105.48104.09
00.10.10.10.10.20.10.30.30.30.30.20.10.90.80.60.60.41.011.815.697.5911.5515.924.835.585.72
000000000000000001.31.471.461.48000000
000000000000000001.51.461.461.46000000
02.11.90.74.41414.226.625.935.735.338.843.858.564.476.385.585.3233.91248.64262.06318.68312.13381.61382.51378.67285.49
00011.72.83.81.53.83.83.81.11.11.71.73.63.63.615.9216.216.5716.5716.5331.2631.2414.714.49
000000000000.100000.40.21.081.892.42.032.392.823.94.725.13
02.221.86.21718.128.43039.839.440.24561.166.980.590.192.3254.85271.45289.66344.86342.6431.61422.47403.67310.83
0.16.64.448.820.726.334.435.747.946.448.956.877.382.3100.7107108282.62320.74338.78403.61407.64508.85503.49509.15414.92
000.30.30.30.31.11.51.51.61.61.722.62.82.42.62.64.684.734.755.185.295.335.385.45.4
0000005.29911.311.311.314.724.324.925.329.429.4108.31109.59110.25144.64149.04150.65151.33151.65151.68
00.10.20.30.3-0.5-4.1-3.7-3-2.5-5.7-3.20.99.216.424.132.338.949.5263.1587.83100.89119.39125.8126.1595.9154.2
0000000000-0.5-1-10000.4-0.1-0.071.790.271.490.46-0.82-0.3712.566.59
000000000000000000000000000
00.10.50.60.6-0.22.26.87.510.46.78.816.636.144.151.864.770.8162.44179.26203.11252.2274.18280.96282.49265.52217.87
04.93.22.72.12.82.72.43.43.32.22.61.73.81.20.91.11.71.555.666.668.986.9711.288.3418.5718.23
00.10.10.20.20.30.610.91.62.32.95.2678.27.256.5712.168.4912.1113.3616.0820.2915.5217.37
000.50.30.100.1000.20.510.73.21.42.51.71.47.836.693.942.152.851.8711.512.324.21
000000000.92.63.12.50.70002.10.40.0300000000
01.400.11.11.922.60.931.72.33.144.310.42.92.915.7825.7842.368.481.030.960.460.610.77
06.43.83.33.555.466.110.79.811.311.41713.9221511.431.7650.2861.3991.7224.2130.1940.5847.0240.57
00004.715.718.621.42225.72927.826.319.819.720.220.919.258.9757.5543.7830.6479.04141.06118.49136.96116.65
00000.10.20000001.53.84.16.16.36.327.8431.4426.9228.6629.8156.1861.7359.4637.86
000.10.1000.20.20.20.911.10.90.70.60.40.20.11.622.23.590.390.40.470.210.21.97
000.10.14.815.918.821.622.226.63028.928.724.324.426.727.425.688.4291.274.2959.69109.25197.71180.43196.61156.48
06.43.93.48.320.924.227.628.337.339.840.240.141.338.348.742.437120.18141.47135.68151.41133.46227.9221243.64197.05
06.54.448.920.726.434.435.847.746.54956.777.482.4100.5107.1107.8282.62320.74338.78403.61407.64508.85503.49509.15414.92
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Alliance Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Alliance Pharma's financial health and stability.

Assets

Alliance Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Alliance Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Alliance Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Alliance Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M GBP)DEPRECIATION (M GBP)DEFERRED TAXES (M GBP)CHANGES IN WORKING CAPITAL (M GBP)NON-CASH ITEM (M GBP)PAID INTEREST (M GBP)PAID TAXES (M GBP)NET CASH FLOW FROM OPERATING ACTIVITIES (M GBP)CAPITAL EXPENDITURES (M GBP)CASH FLOW FROM INVESTING ACTIVITIES (M GBP)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M GBP)INTEREST INCOME AND EXPENSES (M GBP)NET DEBT CHANGE (M GBP)NET CHANGE IN EQUITY (M GBP)CASH FLOW FROM FINANCING ACTIVITIES (M GBP)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M GBP)TOTAL DIVIDENDS PAID (M GBP)NET CHANGE IN CASH FLOW (M GBP)FREE CASH FLOW (M GBP)SHARE-BASED COMPENSATION (M GBP)
1998null19992000null20012002null20032004nullnull200520062007200820092010201120122013201420152016201720182019202020212022
00000000020222-32512101012101522281825870
0000001110100000001001000118161
000000000000000000000000000000
11000-1-1-1-3-2-3-20-100-1-1-3-1-4-1-9-9-2-10-52-10-17
000000000000006354111123-11314222536
000000111111122321111012232224
000000000000000001112213333463
11000000-10-101145101610121011716262235413820
00-10-1-4-12-120-100-10-1-8-30-7-15-6-12-9-2-134-1-2-2-4-4-50
00-10-1-4-12-120-100-10-1-8-3-1-7-15-8-13-9-3-134-8-15-59-3-85-4-17
000000000000000000-20000-6-13-560-810-16
000000000000000000000000000000
00000512123333-151-10-307-2-2521111-1860-2312
0000000014140200370000010344100
00000512125757-260-400-24-5-5128-5-636-2555-340
000000000000-1-2-2-3-2-3-1-1-1078-3-2-3-3-3-2-4
000000000000000000-1-1-2-2-2-5-5-6-7-2-8-9
000000004-34-3-2-1002103-52243061102
0.610-0.89-0.090-5.59-11.60-2.13-10.4400-0.15-7.761.034.882.481.613.34-0.120.138.44-126.5315.5323.8919.2431.636.9633.1320.37
000000000000000000000000000000

Alliance Pharma stock margins

The Alliance Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Alliance Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Alliance Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Alliance Pharma's sales revenue. A higher gross margin percentage indicates that the Alliance Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Alliance Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Alliance Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Alliance Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Alliance Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Alliance Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Alliance Pharma Margin History

Alliance Pharma Gross marginAlliance Pharma Profit marginAlliance Pharma EBIT marginAlliance Pharma Profit margin
2029e58.12 %0 %0 %
2028e58.12 %24.65 %0 %
2027e58.12 %22.46 %14.69 %
2026e58.12 %20.8 %14.69 %
2025e58.12 %20.46 %13.53 %
2024e58.12 %20.94 %12.65 %
202358.12 %19.18 %-18.34 %
202260.74 %16.98 %-12.67 %
202167.06 %18.73 %4.48 %
202063.8 %22.86 %6.18 %
201963.46 %27.61 %18.44 %
201861.46 %24.47 %15.53 %
201758.19 %25.38 %28.36 %
201656.26 %25.96 %18.56 %
201559.43 %25.41 %26.25 %
201457.52 %26.36 %19.26 %
201360.22 %29.45 %21.1 %
201255.9 %27.39 %19.38 %
201153.26 %26.74 %18.7 %
201060.92 %37.47 %18.04 %
200958.01 %35.9 %13.14 %
200850.92 %29.36 %11.47 %
200748.9 %19.78 %-16.48 %
200653.18 %15.03 %2.89 %
200554.47 %16.26 %5.69 %
200452.54 %19.49 %3.39 %

Alliance Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Alliance Pharma earnings per share therefore indicates how much revenue Alliance Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Alliance Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Alliance Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Alliance Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Alliance Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Alliance Pharma Revenue, EBIT and net profit per share

DateAlliance Pharma Sales per ShareAlliance Pharma EBIT per shareAlliance Pharma Earnings per Share
2029e0.48 GBP0 GBP0 GBP
2028e0.47 GBP0 GBP0 GBP
2027e0.44 GBP0 GBP0.06 GBP
2026e0.4 GBP0 GBP0.06 GBP
2025e0.39 GBP0 GBP0.05 GBP
2024e0.36 GBP0 GBP0.05 GBP
20230.33 GBP0.06 GBP-0.06 GBP
20220.31 GBP0.05 GBP-0.04 GBP
20210.3 GBP0.06 GBP0.01 GBP
20200.24 GBP0.06 GBP0.01 GBP
20190.26 GBP0.07 GBP0.05 GBP
20180.23 GBP0.06 GBP0.04 GBP
20170.21 GBP0.05 GBP0.06 GBP
20160.21 GBP0.05 GBP0.04 GBP
20150.17 GBP0.04 GBP0.05 GBP
20140.16 GBP0.04 GBP0.03 GBP
20130.17 GBP0.05 GBP0.04 GBP
20120.17 GBP0.05 GBP0.03 GBP
20110.18 GBP0.05 GBP0.03 GBP
20100.2 GBP0.07 GBP0.04 GBP
20090.15 GBP0.05 GBP0.02 GBP
20080.11 GBP0.03 GBP0.01 GBP
20070 GBP0 GBP-0 GBP
20060.11 GBP0.02 GBP0 GBP
20050.08 GBP0.01 GBP0 GBP
20040.09 GBP0.02 GBP0 GBP

Alliance Pharma business model

Alliance Pharma PLC is a globally operating pharmaceutical company specializing in the marketing and development of pharmaceutical products. The company is headquartered in the United Kingdom and was founded in 1996. Alliance Pharma is one of the most popular companies on Eulerpool.com.

Alliance Pharma SWOT Analysis

Strengths

Alliance Pharma PLC has established a strong market position in the pharmaceutical industry, allowing them to leverage their brand and reputation for continued growth.

The company boasts a diversified product portfolio, which reduces dependency on a single drug or therapeutic area. This offers resilience against market fluctuations and enhances long-term sustainability.

Alliance Pharma PLC has a track record of successful strategic acquisitions, enabling them to expand their product range and enter new markets. These acquisitions have added value to the company and contributed to its growth.

The company has developed strong relationships with healthcare professionals, including doctors and pharmacists, who trust and recommend Alliance Pharma PLC's products. This ensures a steady customer base and potential for further growth.

Weaknesses

Alliance Pharma PLC's operations are primarily focused in the UK, limiting their exposure to international markets. This could be a potential weakness as it constrains their growth opportunities beyond their domestic market.

The company relies on third-party suppliers for the manufacturing and supply of their products. Any disruptions or issues with these suppliers could impact Alliance Pharma PLC's ability to meet customer demand and affect their business operations.

Opportunities

Alliance Pharma PLC has the opportunity to expand into emerging markets, such as Asia and Latin America, where there is a growing demand for pharmaceutical products. This would diversify their customer base and increase revenue potential.

The company can capitalize on the increasing demand for niche therapeutic areas, such as dermatology or rare diseases, by developing specialized products or acquiring companies with expertise in those areas. This would allow them to tap into unmet medical needs and gain a competitive advantage.

Threats

Alliance Pharma PLC faces intense competition from other pharmaceutical companies, both large and small. This competitive environment could impact their market share and put pressure on pricing and profitability.

The pharmaceutical industry is subject to stringent regulatory requirements, which can create barriers to market entry and increase compliance costs. Non-compliance or regulatory changes could negatively impact Alliance Pharma PLC's operations.

Alliance Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Alliance Pharma historical P/E ratio, EBIT, and P/S ratio.

Alliance Pharma shares outstanding

The number of shares was Alliance Pharma in 2023 — This indicates how many shares 540.145 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Alliance Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Alliance Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Alliance Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Alliance Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Alliance Pharma dividend history and estimates

In 2023, Alliance Pharma paid a dividend amounting to 0.02 GBP. Dividend means that Alliance Pharma distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Alliance Pharma provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Alliance Pharma’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Alliance Pharma's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Alliance Pharma Dividend History

DateAlliance Pharma Dividend
2029e0.02 GBP
2028e0.02 GBP
2027e0.02 GBP
2026e0.02 GBP
2025e0.02 GBP
2024e0.02 GBP
20230.02 GBP
20220.02 GBP
20210.02 GBP
20200.01 GBP
20190.02 GBP
20180.01 GBP
20170.01 GBP
20160.01 GBP
20150.01 GBP
20140.01 GBP
20130.01 GBP
20120.01 GBP
20110.01 GBP
20100 GBP
20090 GBP

Alliance Pharma dividend payout ratio

In 2023, Alliance Pharma had a payout ratio of 76.97%. The payout ratio indicates the percentage of the company's profits that Alliance Pharma distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Alliance Pharma represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Alliance Pharma could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Alliance Pharma's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Alliance Pharma Payout Ratio History

DateAlliance Pharma Payout ratio
2029e97.52 %
2028e100.79 %
2027e98.58 %
2026e93.18 %
2025e110.62 %
2024e91.94 %
202376.97 %
2022-43.75 %
2021162.96 %
202035.88 %
201932.08 %
201838.24 %
201720.77 %
201629.76 %
201525.24 %
201433.01 %
201323.69 %
201228.7 %
201124.07 %
201011.11 %
20093.89 %
200876.97 %
200776.97 %
200676.97 %
200576.97 %
200476.97 %
Unfortunately, there are currently no price targets and forecasts available for Alliance Pharma.

Alliance Pharma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/20230.03 GBP0.03 GBP (-1 %)2023 Q4
6/30/20230.02 GBP0.02 GBP (-23.3 %)2023 Q2
12/31/20220.02 GBP0.01 GBP (-11.61 %)2022 Q4
6/30/20220.03 GBP0.03 GBP (9.16 %)2022 Q2
12/31/20210.03 GBP0.03 GBP (12.37 %)2021 Q4
6/30/20210.03 GBP0.03 GBP (5.76 %)2021 Q2
12/31/20140.02 GBP0.02 GBP (1.21 %)2014 Q4
12/31/20130.02 GBP0.02 GBP (-7.74 %)2013 Q4
6/30/20130.02 GBP0.02 GBP (17.03 %)2013 Q2
12/31/20120.02 GBP0.02 GBP (2.4 %)2012 Q4
1
2

Eulerpool ESG Scorecard© for the Alliance Pharma stock

Eulerpool World ESG Rating (EESG©)

67/ 100

🌱 Environment

72

👫 Social

65

🏛️ Governance

63

Environment

Scope 1 - Direct Emissions
2
Scope 2 - Indirect emissions from purchased energy
50
Scope 3 - Indirect emissions within the value chain
47,973
Total CO₂ emissions
52
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
✅
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees58
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Alliance Pharma list of shareholders

%
Name
Stocks
Change
Date
5.36 % Logistics Development Group PLC28,966,35410,280,3123/21/2023
3.63 % Fidelity Management & Research Company LLC19,644,02505/3/2023
3.47 % Rathbones Investment Management Limited18,774,072-130,80910/6/2023
3.41 % Canaccord Genuity Wealth Management18,422,86310,822,8635/3/2023
3.00 % Dawson (John Andrew)16,200,462324,0603/17/2023
21.08 % DBAY Advisors, Ltd.113,965,22014,000,0009/1/2023
2.69 % RBC Global Asset Management (UK) Limited14,546,460-6,098,7768/25/2023
10.20 % Kempen Capital Management (UK) Ltd.55,157,3483,851,26611/6/2023
10.01 % Slater Investments Ltd.54,122,7812,216,7409/21/2023
1.81 % Artemis Investment Management LLP9,766,943-2,438,2549/1/2023
1
2
3
4
5
...
10

Alliance Pharma Executives and Management Board

Mr. Peter Butterfield
Alliance Pharma Chief Executive Officer, Executive Director (since 2010)
Compensation 399,832 GBP
Mr. Andrew Franklin
Alliance Pharma Chief Financial Officer, Executive Director (since 2015)
Compensation 271,520 GBP
Ms. Jo Couilliard
Alliance Pharma Independent Non-Executive Chairman of the Board
Compensation 49,458 GBP
Mr. Richard Jones
Alliance Pharma Senior Non-Executive Independent Director
Compensation 49,458 GBP
Mr. Kristof Neirynck
Alliance Pharma Non-Executive Independent Director
Compensation 47,201 GBP
1
2
3

Alliance Pharma Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
BlackRock Stock
BlackRock
SupplierCustomer0,760,670,13-0,37-0,490,65
Van Lanschot Kempen Stock
Van Lanschot Kempen
SupplierCustomer0,19-0,290,670,730,530,78
DCC Stock
DCC
SupplierCustomer0,150,260,400,120,08-0,04
Venture Life Group Stock
Venture Life Group
SupplierCustomer-0,180,550,250,01-0,44-0,72
Valeo Pharma A Stock
Valeo Pharma A
SupplierCustomer-0,480,12----
1

Most common questions regarding Alliance Pharma

What values and corporate philosophy does Alliance Pharma represent?

Alliance Pharma PLC represents strong values and corporate philosophy in its operations. The company focuses on providing innovative healthcare solutions to improve patient outcomes and enhance the quality of life. Alliance Pharma prioritizes integrity, accountability, and transparency in all aspects of its business. With a customer-centric approach, the company aims to deliver high-quality products and services, while fostering strong relationships with healthcare professionals and patients. Alliance Pharma is committed to driving growth, expanding its product portfolio, and ensuring regulatory compliance. Through continuous research and development, the company strives to address unmet medical needs and contribute positively to the healthcare industry.

In which countries and regions is Alliance Pharma primarily present?

Alliance Pharma PLC is primarily present in the United Kingdom, Europe, and international markets.

What significant milestones has the company Alliance Pharma achieved?

Alliance Pharma PLC has achieved several significant milestones throughout its history. The company has demonstrated consistent growth and expansion, with a strong focus on strategic acquisitions and partnerships. Notably, Alliance Pharma successfully completed the acquisition of Sinclair Pharma's dermatology division in 2015, enhancing its product portfolio and market presence. It has also achieved key regulatory approvals for various products, enabling global distribution and sales. Additionally, Alliance Pharma has consistently delivered strong financial performance, with steady revenue growth and increased profitability over the years. These milestones signify the company's commitment to innovation, market leadership, and delivering value to its shareholders.

What is the history and background of the company Alliance Pharma?

Alliance Pharma PLC is a reputable and established pharmaceutical company with a rich history. It was founded in 1998 and is headquartered in the United Kingdom. The company focuses on acquiring and licensing healthcare products and medicines to expand its extensive portfolio. Alliance Pharma PLC has successfully grown through collaborations with other pharmaceutical companies, allowing them to offer an extensive range of prescription and over-the-counter products to consumers. With a steadfast commitment to innovation and quality, Alliance Pharma PLC has become a trusted name in the healthcare industry, providing reliable and effective solutions for various medical needs.

Who are the main competitors of Alliance Pharma in the market?

The main competitors of Alliance Pharma PLC in the market include companies such as GlaxoSmithKline, AstraZeneca, Pfizer, and Johnson & Johnson. These pharmaceutical giants are notable players in the industry and offer similar products and services as Alliance Pharma PLC. Despite the competitive landscape, Alliance Pharma PLC strives to stand out with its unique offerings and solutions, consistently delivering high-quality pharmaceutical products that cater to the needs of customers.

In which industries is Alliance Pharma primarily active?

Alliance Pharma PLC is primarily active in the pharmaceutical industry.

What is the business model of Alliance Pharma?

Alliance Pharma PLC operates as a specialty pharmaceutical company. It focuses on acquiring, marketing, and distributing pharmaceutical products, as well as providing support services to healthcare professionals and patients. The company's business model revolves around sourcing and acquiring the rights to pharmaceutical and healthcare products, implementing sales and marketing strategies, and maintaining strong customer relationships. Alliance Pharma PLC aims to deliver sustainable growth through its diversified product portfolio, enhancing operational efficiency, and expanding its global presence in niche therapeutic areas.

What is the P/E ratio of Alliance Pharma 2024?

The Alliance Pharma P/E ratio is 8.19.

What is the P/S ratio of Alliance Pharma 2024?

The Alliance Pharma P/S ratio is 1.04.

What is the AlleAktien quality score of Alliance Pharma?

The AlleAktien quality score for Alliance Pharma is 6/10.

What is the revenue of Alliance Pharma 2024?

The expected Alliance Pharma revenue is 195.03 M GBP.

How high is the profit of Alliance Pharma 2024?

The expected Alliance Pharma profit is 24.66 M GBP.

What is the business model of Alliance Pharma

Alliance Pharma PLC is a British company specializing in the development, manufacturing, and marketing of over-the-counter medicines and healthcare products. The company offers a wide range of products in various business sectors, including dermatological products, pain relievers, infection protection, orthopedic products, and ophthalmological products. Alliance Pharma distributes its products in several European countries and other international markets through online platforms, pharmacies, and drugstores. The company aims to expand its business model by acquiring other companies and developing new products in different categories. With a strong commitment to innovation and customer service, Alliance Pharma has a solid foundation and promising growth prospects for the future.

What is the Alliance Pharma dividend?

Alliance Pharma pays a dividend of 0.02 GBP distributed over payouts per year.

How often does Alliance Pharma pay dividends?

The dividend cannot currently be calculated for Alliance Pharma or the company does not pay out a dividend.

What is the Alliance Pharma ISIN?

The ISIN of Alliance Pharma is GB0031030819.

What is the Alliance Pharma WKN?

The WKN of Alliance Pharma is 913253.

What is the Alliance Pharma ticker?

The ticker of Alliance Pharma is APH.L.

How much dividend does Alliance Pharma pay?

Over the past 12 months, Alliance Pharma paid a dividend of 0.02 GBP . This corresponds to a dividend yield of about 6.33 %. For the coming 12 months, Alliance Pharma is expected to pay a dividend of 0.02 GBP.

What is the dividend yield of Alliance Pharma?

The current dividend yield of Alliance Pharma is 6.33 %.

When does Alliance Pharma pay dividends?

Alliance Pharma pays a quarterly dividend. This is distributed in the months of January, July, January, July.

How secure is the dividend of Alliance Pharma?

Alliance Pharma paid dividends every year for the past 0 years.

What is the dividend of Alliance Pharma?

For the upcoming 12 months, dividends amounting to 0.02 GBP are expected. This corresponds to a dividend yield of 6.39 %.

In which sector is Alliance Pharma located?

Alliance Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alliance Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alliance Pharma from 7/18/2023 amounting to 0.012 GBP, you needed to have the stock in your portfolio before the ex-date on 6/22/2023.

When did Alliance Pharma pay the last dividend?

The last dividend was paid out on 7/18/2023.

What was the dividend of Alliance Pharma in the year 2023?

In the year 2023, Alliance Pharma distributed 0.017 GBP as dividends.

In which currency does Alliance Pharma pay out the dividend?

The dividends of Alliance Pharma are distributed in GBP.

All fundamentals about Alliance Pharma

Our stock analysis for Alliance Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alliance Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.